Frankfurt
27.02.26 | 08:09
0,056 Euro
-34,80 % -0,030
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 174 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 64 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 161 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 164 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 316 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 216 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen | |
| 26.08.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 183 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07.25 | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 261 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 12.06.25 | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | 335 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen | |
| 12.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.06.2025 | 467 | Xetra Newsboard | Das Instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 12.06.2025 The instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.06.25 | Isofol Medical AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025 | 229 | GlobeNewswire (Europe) | GOTHENBURG, 11 June 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at which the following main resolutions were passed by the shareholders.
The... ► Artikel lesen | |
| 05.06.25 | Isofol Medical AB: Isofol announces final terms of the rights issue and the potential overallotment issue | 277 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 5 June 2025 - The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol" or the "Company") announced on 12 May 2025, that the Board of Directors, subject... ► Artikel lesen | |
| 21.05.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | 199 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen | |
| 03.04.25 | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | 467 | Edison Investment Research | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,700 | -0,63 % | Bayer Aktie: Alles vorbei? - Airbus, BB Biotech, BioNTech, TUI und Valneva - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,438 | +0,86 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARDIOL THERAPEUTICS | 0,920 | +6,11 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference |
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| ATAIBECKLEY | 3,040 | -6,75 % | atai Life Sciences & Compass Pathways treiben Psychedelika-Boom - Warum Emyria jetzt strategisch im Zentrum steht | ||
| BIOMERIEUX | 100,50 | +0,95 % | BioMerieux SA Profit Declines In Full Year | PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share.... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,990 | 0,00 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 32,200 | -11,05 % | Genus PLC - Director/PDMR Shareholding | ||
| ANAPTYSBIO | 47,400 | +2,16 % | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology... ► Artikel lesen | |
| ABIONYX PHARMA | 3,270 | +2,83 % | ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025 | Consolidated revenue of €4.1 million at the end of December 2025 Cash position of €3.5 million as of December 31, 2025 Cash runway through year-end 2026 excluding France 2030 non-dilutive... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,575 | -0,86 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing | RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter")... ► Artikel lesen | |
| AKESO | 11,400 | 0,00 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| MEIRAGTX | 6,350 | -2,31 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,056 Euro und damit -34,80 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.